Amgen Inc.
AMGNAmgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
Drugs in Pipeline
212
Phase 3 Programs
117
Upcoming Catalysts
13
Next Catalyst
This month
Market Overview
Stock performance and key metrics
13 upcoming, 4 past
Dazodalibep Phase 3 Est. Readout
Primary completion for Dazodalibep trial (NCT06245408) in Sjögren's Syndrome (SS)
Source12 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How AMGN's past catalysts played out
Lumakras
Sotorasib
KRAS G12C NSCLC
Pegloticase
Uncontrolled Gout
MR prednisone
Rheumatoid Arthritis
HZT-501
Osteoarthritis
Trifluridine and Tipiracil
Colorectal Cancer (CRC)
Apremilast (CC-10004)
Behcet Syndrome
Vincrisitne
Leukemia, Acute Lymphoblastic
Lanadelumab
COVID-19
ABP 938 8 mg
Neovascular Age-related Macular Degeneration
MP-376 (Levofloxacin Solution for Inhalation)
Cystic Fibrosis
De Novo Administration of Darbepoetin Alfa
Chronic Kidney Disease
Apremilast 30mg
Psoriatic Arthritis
darbepoetin alfa
Anemia
Zoledronic Acid
Bone Metastases
Denosumab
Osteoporosis
Oxaliplatin Based Chemotherapy
Colorectal Cancer
Statin therapy
Coronary Artery Disease (CAD)
pegfilgrastim
Breast Cancer
Inebilizumab
IgG4 Related Disease
ABP 234
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
ABP 501
Arthritis, Rheumatoid
Olpasiran
Cardiovascular Disease
Romiplostim
Chemotherapy-induced Thrombocytopenia
AMG 531
Thrombocytopenia
Bemarituzumab
Gastric Cancer
Etanercept
Rheumatoid Arthritis
alendronate
Osteoporosis
Erenumab
Migraine
Maridebart cafraglutide
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Aeroquin
Cystic Fibrosis
Commercial Formulation Etanercept
Arthritis, Rheumatoid; Arthritis, Psoriatic
ABP 959
Paroxysmal Nocturnal Hemoglobinuria
Apremilast
Behçet's Disease
Etelcalcetide
Secondary Hyperparathyroidism
Panitumumab
Metastatic Colorectal Cancer
Cinacalcet
End Stage Renal Disease
Cystagon® (Cysteamine Bitartrate)
Cystinosis
Evolocumab
Hyperlipidemia
darbepoetin alfa SF
Kidney Disease
FOLFIRI Regimen
Metastatic Colorectal Cancer
Avacopan
Vasculitis
Lurbinectedin
Small Cell Lung Cancer (SCLC)
ABP 798
Arthritis, Rheumatoid
ABP 980
Breast Cancer
Rocatinlimab
Asthma
Topical Therapy
Plaque Psoriasis
FOLFOX regimen
Metastatic Colorectal Cancer
RP103
Cystinosis
Blinatumomab
Acute Lymphoblastic Leukemia
AMG 073
Secondary Hyperparathyroidism
Aranesp®
Kidney Disease
rHuEPO
Cancer
Apremilast 20mg
Psoriatic Arthritis
Evolocumab AMD
Primary Hypercholesterolemia
Risendronate
Steroid-induced Osteopor, Glucocorticoid-induced Ostepor
Epoetin alfa RB
Nephrology
Actonel®
Osteoporosis
Background Statin Therapy
Dyslipidemia
ABP 938
Neovascular (Wet) Age-related Macular Degeneration (AMD)
Cystagon®
Cystinosis
60 mg denosumab
Low Bone Mass
Best Supportive Care
Multiple Myeloma
mFOLFOX6
Gastric Cancer
Romosozumab 90 mg/mL
Postmenopausal Osteoporosis
Denosumab (CP2)
Postmenopausal Osteoporosis
Ustekinumab
Psoriasis
Topical treatments or phototherapy
Plaque Psoriasis
Standard Chemotherapy
Cancer
etanercept pre-filled syringe subcutaneous injection
Rheumatoid Arthritis
Teprotumumab
Thyroid Eye Disease
1=Etanercept
Psoriasis
Non-steroidal aromatase inhibitor therapy
Breast Cancer
Ibuprofen/famotidine
Ulcer
interferon γ-1b
Friedreich's Ataxia
Ocrelizumab (US)
Relapsing-remitting Multiple Sclerosis (RRMS)
Ibandronate
Postmenopausal Osteoporosis
ABP 710
Arthritis, Rheumatoid
Sotorasib
Non-small Cell Lung Cancer
AMG 510
KRAS p, G12c Mutated /Advanced Metastatic NSCLC
Xaluritamig
Metastatic Castration-resistant Prostate Cancer
Erenumab Dose 1
Migraine
Etanercept / Autoinjector A
Rheumatoid Arthritis
TAC
Breast Cancer
ABP 654
Plaque Psoriasis
Erenumab Dose 2
Migraine
Denosumab (for the open-label treatment phase)
Cancer
Dazodalibep
Sjögren's Syndrome (SS)
Topical agents
Psoriasis
AMG 162
Postmenopausal Osteoporosis
Cinacalcet HCl
Kidney Disease
HPN-100
Cirrhosis
Low-intensity chemotherapy regimen
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Palifermin
Head and Neck Cancer
Darbepoetin alfa and Epoetin alfa
Anemia
Apremilast 30 mg
Psoriatic Arthritis
Atorvastatin
Hyperlipidemia
Omnipaque
Cardiovascular Disease
Tarlatamab
Small Cell Lung Cancer
Etanercept Liquid
Rheumatoid Arthritis
romosozumab HCP administration with PFS
Post-Menopausal Osteoporosis
Denosumab (AMG 162)
Postmenopausal Osteoporosis
AMG 162 / Denosumab
Breast Cancer
Darbepoetin alfa - 2.25 mcg/kg
Anemia
ABP 206
Melanoma
Apremilast tablet 20 mg
Ankylosing Spondyloarthritis
50 mg Etanercept
Rheumatoid Arthritis
Epoetin alfa DT
Chronic Kidney Disease
Romosozumab
Postmenopausal Women With Osteoporosis
ARM 2
Recurrent and/or Metastatic Head and Neck Cancer
Chemotherapy
Gastric Cancer
Recombinant Human Keratinocyte Growth Factor
Stomatitis
Anakinra (Kineret®)
Rheumatoid Arthritis
Aranesp® (darbepoetin alfa)
Kidney Disease
AMG 386
Ovarian Cancer
Cysteamine Bitartrate Delayed-release Capsules
Cystinosis
Evolocumab Pre-filled Syringe
Primary Hypercholesterolemia
Romozosumab
Postmenopausal Osteoporosis
Buphenyl (NaPBA)
Urea Cycle Disorders
Tezepelumab Dose 1
Chronic Spontaneous Urticaria
AMG 102 at 20 mg/kg
Advanced Malignant Glioma
AMG 108
Rheumatoid Arthritis
Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)
Anemia
Cysteamine Bitartrate
Inherited Mitochondrial Disease, Including Leigh Syndrome
Recombinant Human Erythropoietin
Breast Cancer
CC10004
Psoriasis
CCX 354-C
Rheumatoid Arthritis
Epirubicin, Cisplatin, Capecitabine, Panitumumab
Stomach Neoplasms
CCX168
Vasculitis
ABX-EGF (panitumumab)
Metastatic Colorectal Cancer
Adecatumumab
Liver Metastases
AMG 531 (Romiplostim)
MDS
IDE397
MTAP-null Non-Small-Cell Lung Cancer
IV Bisphosphonates
Breast Cancer
recombinant human erythropoietin (rHuEPO)
Gynecological Malignancies
RAD
Multiple Myeloma
AMG 706
Gastrointestinal Cancer
AMG 951 (rhApo2L/TRAIL)
Non-Small Cell Lung Cancer
Interferon gamma-1b
Acute Myeloid Leukemia
Darbepoetin alfa SC
Anemia
HZN-1116
Sjogren's Syndrome
AMG 337
Stomach Neoplasms
pegfilgrastim 12 mg
Lymphoma
Investigator's Choice Chemotherapy
High-risk Diffuse Large B-Cell Lymphoma
Rozibafusp Alfa
Systemic Lupus Erythematosus (SLE)
5-Fluorouracil
Colorectal Cancer
Panitumumab (ABX-EGF)
Advanced Renal Cell Carcinoma
Talimogene laherparepvec
Melanoma
AMG 853
Asthma
epratuzumab
Non-Hodgkin's Lymphoma
cinacalcet (AMG 073)
Secondary Hyperparathyroidism
AMG 193
MTAP-deleted NSCLC
Apremilast 10mg
Psoriasis
Antizol
Aldehyde Dehydrogenase-2 (ALDH2) Deficiency
VIB7734
Lupus Erythematosus, Systemic
Systemic AMG 108
Osteoarthritis
Modified FOLFOX6
Advanced Solid Tumors
Blinatumomab (MT103)
Acute Lymphoblastic Leukemia
AMG 334
Post-Traumatic Headache
AMG 827
Asthma
IV Bisphosphonate q 4 weeks
Bone Metastases in Men With Hormone-Refractory Prostate Cancer
Pegsunercept (PEG sTNF-RI)
Rheumatoid Arthritis
MP-376
Cystic Fibrosis (CF)
AMG 386 10mg/kg
Gastrointestinal Cancer
Lodotra
Asthma
CPT-11
Non Small Cell Lung Cancer
Naproxen
Bone Pain in Stage I - III Breast Cancer
CCX282-B
Crohn's Disease
Teriparatide
Low Bone Mineral Density
5FU
Squamous Cell Carcinoma of Head and Neck
Carfilzomib
Multiple Myeloma
anakinra
Rheumatoid Arthritis
CC-10004
Psoriasis
CCX140-B
Diabetic Nephropathy
AMG 317 75 mg
Asthma
AMG 223
End Stage Renal Disease
Oprozomib
Multiple Myeloma
AMG 102 at 10 mg/kg
Advanced Renal Cell Carcinoma
AMG 655
Metastatic Colorectal Cancer
BUPHENYL®
Urea Cycle Disorders
CCX-354-C
Rheumatoid Arthritis
100 mg AMG 162
Osteoporosis
Liatermin
Parkinson's Disease
NaPBA
Urea Cycle Disorders
Previous denosumab
Low Bone Mass
filgrastim
Sarcoma
Daxdilimab
Alopecia Areata
Sensipar (Cinacalcet HCl)
Secondary Hyperparathyroidism
ABX-EGF
Non-small Cell Lung Cancer
Motesanib diphosphate
Lung Cancer
VIB4920
Sjögren's Syndrome
AMG 151
Diabetes Mellitus
Intra-articular metHuIL-1ra (anakinra)
Osteoarthritis
Belatacept
Allografts
Conatumumab
Colon Cancer
liposomal cytarabine
Primary Disease
Cytarabine
Lymphoma
IV iron dextran
Anemia
Neulasta
Breast Cancer
CEEP regimen
Lymphoma
AMG 714
Psoriasis
CC-11050
Cutaneous Lupus Erythematosus
AMG 102
Cancer
Ezetimibe
Hyperlipidemia
RCHOP
Richter Syndrome
Romidepsin
Peripheral T Cell Lymphoma
AMG 719
Rheumatoid Arthritis
AMG 301
Chronic Migraine or Episodic Migraine
AMG 732
Thyroid Eye Disease
Abrilumab
Ulcerative Colitis
Erenumab PFS
Migraine
Brodalumab
Rheumatoid Arthritis
AMG 509
Prostate Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Lumakras Sotorasib | Approved | KRAS G12C NSCLC | Fast TrackBreakthrough | Patent 2040 |
Pegloticase | Phase 3 | Uncontrolled Gout | - | - |
MR prednisone | Phase 3 | Rheumatoid Arthritis | - | - |
HZT-501 | Phase 3 | Osteoarthritis | - | - |
Trifluridine and Tipiracil | Phase 3 | Colorectal Cancer (CRC) | - | - |
Apremilast (CC-10004) | Phase 3 | Behcet Syndrome | - | - |
Vincrisitne | Phase 3 | Leukemia, Acute Lymphoblastic | - | - |
Lanadelumab | Phase 3 | COVID-19 | - | - |
ABP 938 8 mg | Phase 3 | Neovascular Age-related Macular Degeneration | - | - |
MP-376 (Levofloxacin Solution for Inhalation) | Phase 3 | Cystic Fibrosis | - | - |
De Novo Administration of Darbepoetin Alfa | Phase 3 | Chronic Kidney Disease | - | - |
Apremilast 30mg | Phase 3 | Psoriatic Arthritis | - | - |
darbepoetin alfa | Phase 3 | Anemia | - | - |
Zoledronic Acid | Phase 3 | Bone Metastases | - | - |
Denosumab | Phase 3 | Osteoporosis | - | - |
Oxaliplatin Based Chemotherapy | Phase 3 | Colorectal Cancer | - | - |
Statin therapy | Phase 3 | Coronary Artery Disease (CAD) | - | - |
pegfilgrastim | Phase 3 | Breast Cancer | - | - |
Inebilizumab | Phase 3 | IgG4 Related Disease | - | - |
ABP 234 | Phase 3 | Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer | - | - |
ABP 501 | Phase 3 | Arthritis, Rheumatoid | - | - |
Olpasiran | Phase 3 | Cardiovascular Disease | - | - |
Romiplostim | Phase 3 | Chemotherapy-induced Thrombocytopenia | - | - |
AMG 531 | Phase 3 | Thrombocytopenia | - | - |
Bemarituzumab | Phase 3 | Gastric Cancer | - | - |
Etanercept | Phase 3 | Rheumatoid Arthritis | - | - |
alendronate | Phase 3 | Osteoporosis | - | - |
Erenumab | Phase 3 | Migraine | - | - |
Maridebart cafraglutide | Phase 3 | Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight | - | - |
Aeroquin | Phase 3 | Cystic Fibrosis | - | - |
Commercial Formulation Etanercept | Phase 3 | Arthritis, Rheumatoid; Arthritis, Psoriatic | - | - |
ABP 959 | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
Apremilast | Phase 3 | Behçet's Disease | - | - |
Etelcalcetide | Phase 3 | Secondary Hyperparathyroidism | - | - |
Panitumumab | Phase 3 | Metastatic Colorectal Cancer | - | - |
Cinacalcet | Phase 3 | End Stage Renal Disease | - | - |
Cystagon® (Cysteamine Bitartrate) | Phase 3 | Cystinosis | - | - |
Evolocumab | Phase 3 | Hyperlipidemia | - | - |
darbepoetin alfa SF | Phase 3 | Kidney Disease | - | - |
FOLFIRI Regimen | Phase 3 | Metastatic Colorectal Cancer | - | - |
Avacopan | Phase 3 | Vasculitis | - | - |
Lurbinectedin | Phase 3 | Small Cell Lung Cancer (SCLC) | - | - |
ABP 798 | Phase 3 | Arthritis, Rheumatoid | - | - |
ABP 980 | Phase 3 | Breast Cancer | - | - |
Rocatinlimab | Phase 3 | Asthma | - | - |
Topical Therapy | Phase 3 | Plaque Psoriasis | - | - |
FOLFOX regimen | Phase 3 | Metastatic Colorectal Cancer | - | - |
RP103 | Phase 3 | Cystinosis | - | - |
Blinatumomab | Phase 3 | Acute Lymphoblastic Leukemia | - | - |
AMG 073 | Phase 3 | Secondary Hyperparathyroidism | - | - |
Aranesp® | Phase 3 | Kidney Disease | - | - |
rHuEPO | Phase 3 | Cancer | - | - |
Apremilast 20mg | Phase 3 | Psoriatic Arthritis | - | - |
Evolocumab AMD | Phase 3 | Primary Hypercholesterolemia | - | - |
Risendronate | Phase 3 | Steroid-induced Osteopor, Glucocorticoid-induced Ostepor | - | - |
Epoetin alfa RB | Phase 3 | Nephrology | - | - |
Actonel® | Phase 3 | Osteoporosis | - | - |
Background Statin Therapy | Phase 3 | Dyslipidemia | - | - |
ABP 938 | Phase 3 | Neovascular (Wet) Age-related Macular Degeneration (AMD) | - | - |
Cystagon® | Phase 3 | Cystinosis | - | - |
60 mg denosumab | Phase 3 | Low Bone Mass | - | - |
Best Supportive Care | Phase 3 | Multiple Myeloma | - | - |
mFOLFOX6 | Phase 3 | Gastric Cancer | - | - |
Romosozumab 90 mg/mL | Phase 3 | Postmenopausal Osteoporosis | - | - |
Denosumab (CP2) | Phase 3 | Postmenopausal Osteoporosis | - | - |
Ustekinumab | Phase 3 | Psoriasis | - | - |
Topical treatments or phototherapy | Phase 3 | Plaque Psoriasis | - | - |
Standard Chemotherapy | Phase 3 | Cancer | - | - |
etanercept pre-filled syringe subcutaneous injection | Phase 3 | Rheumatoid Arthritis | - | - |
Teprotumumab | Phase 3 | Thyroid Eye Disease | - | - |
1=Etanercept | Phase 3 | Psoriasis | - | - |
Non-steroidal aromatase inhibitor therapy | Phase 3 | Breast Cancer | - | - |
Ibuprofen/famotidine | Phase 3 | Ulcer | - | - |
interferon γ-1b | Phase 3 | Friedreich's Ataxia | - | - |
Ocrelizumab (US) | Phase 3 | Relapsing-remitting Multiple Sclerosis (RRMS) | - | - |
Ibandronate | Phase 3 | Postmenopausal Osteoporosis | - | - |
ABP 710 | Phase 3 | Arthritis, Rheumatoid | - | - |
Sotorasib | Phase 3 | Non-small Cell Lung Cancer | - | - |
AMG 510 | Phase 3 | KRAS p, G12c Mutated /Advanced Metastatic NSCLC | - | - |
Xaluritamig | Phase 3 | Metastatic Castration-resistant Prostate Cancer | - | - |
Erenumab Dose 1 | Phase 3 | Migraine | - | - |
Etanercept / Autoinjector A | Phase 3 | Rheumatoid Arthritis | - | - |
TAC | Phase 3 | Breast Cancer | - | - |
ABP 654 | Phase 3 | Plaque Psoriasis | - | - |
Erenumab Dose 2 | Phase 3 | Migraine | - | - |
Denosumab (for the open-label treatment phase) | Phase 3 | Cancer | - | - |
Dazodalibep | Phase 3 | Sjögren's Syndrome (SS) | - | - |
Topical agents | Phase 3 | Psoriasis | - | - |
AMG 162 | Phase 3 | Postmenopausal Osteoporosis | - | - |
Cinacalcet HCl | Phase 3 | Kidney Disease | - | - |
HPN-100 | Phase 3 | Cirrhosis | - | - |
Low-intensity chemotherapy regimen | Phase 3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | - | - |
Palifermin | Phase 3 | Head and Neck Cancer | - | - |
Darbepoetin alfa and Epoetin alfa | Phase 3 | Anemia | - | - |
Apremilast 30 mg | Phase 3 | Psoriatic Arthritis | - | - |
Atorvastatin | Phase 3 | Hyperlipidemia | - | - |
Omnipaque | Phase 3 | Cardiovascular Disease | - | - |
Tarlatamab | Phase 3 | Small Cell Lung Cancer | OrphanFast TrackBreakthrough | |
Etanercept Liquid | Phase 3 | Rheumatoid Arthritis | - | - |
romosozumab HCP administration with PFS | Phase 3 | Post-Menopausal Osteoporosis | - | - |
Denosumab (AMG 162) | Phase 3 | Postmenopausal Osteoporosis | - | - |
AMG 162 / Denosumab | Phase 3 | Breast Cancer | - | - |
Darbepoetin alfa - 2.25 mcg/kg | Phase 3 | Anemia | - | - |
ABP 206 | Phase 3 | Melanoma | - | - |
Apremilast tablet 20 mg | Phase 3 | Ankylosing Spondyloarthritis | - | - |
50 mg Etanercept | Phase 3 | Rheumatoid Arthritis | - | - |
Epoetin alfa DT | Phase 3 | Chronic Kidney Disease | - | - |
Romosozumab | Phase 3 | Postmenopausal Women With Osteoporosis | - | - |
ARM 2 | Phase 3 | Recurrent and/or Metastatic Head and Neck Cancer | - | - |
Chemotherapy | Phase 3 | Gastric Cancer | - | - |
Recombinant Human Keratinocyte Growth Factor | Phase 3 | Stomatitis | - | - |
Anakinra (Kineret®) | Phase 3 | Rheumatoid Arthritis | - | - |
Aranesp® (darbepoetin alfa) | Phase 3 | Kidney Disease | - | - |
AMG 386 | Phase 3 | Ovarian Cancer | - | - |
Cysteamine Bitartrate Delayed-release Capsules | Phase 3 | Cystinosis | - | - |
Evolocumab Pre-filled Syringe | Phase 3 | Primary Hypercholesterolemia | - | - |
Romozosumab | Phase 3 | Postmenopausal Osteoporosis | - | - |
Buphenyl (NaPBA) | Phase 3 | Urea Cycle Disorders | - | - |
Tezepelumab Dose 1 | Phase 2 | Chronic Spontaneous Urticaria | - | - |
AMG 102 at 20 mg/kg | Phase 2 | Advanced Malignant Glioma | - | - |
AMG 108 | Phase 2 | Rheumatoid Arthritis | - | - |
Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa) | Phase 2 | Anemia | - | - |
Cysteamine Bitartrate | Phase 2 | Inherited Mitochondrial Disease, Including Leigh Syndrome | - | - |
Recombinant Human Erythropoietin | Phase 2 | Breast Cancer | - | - |
CC10004 | Phase 2 | Psoriasis | - | - |
CCX 354-C | Phase 2 | Rheumatoid Arthritis | - | - |
Epirubicin, Cisplatin, Capecitabine, Panitumumab | Phase 2 | Stomach Neoplasms | - | - |
CCX168 | Phase 2 | Vasculitis | - | - |
ABX-EGF (panitumumab) | Phase 2 | Metastatic Colorectal Cancer | - | - |
Adecatumumab | Phase 2 | Liver Metastases | - | - |
AMG 531 (Romiplostim) | Phase 2 | MDS | - | - |
IDE397 | Phase 2 | MTAP-null Non-Small-Cell Lung Cancer | - | - |
IV Bisphosphonates | Phase 2 | Breast Cancer | - | - |
recombinant human erythropoietin (rHuEPO) | Phase 2 | Gynecological Malignancies | - | - |
RAD | Phase 2 | Multiple Myeloma | - | - |
AMG 706 | Phase 2 | Gastrointestinal Cancer | - | - |
AMG 951 (rhApo2L/TRAIL) | Phase 2 | Non-Small Cell Lung Cancer | - | - |
Interferon gamma-1b | Phase 2 | Acute Myeloid Leukemia | - | - |
Darbepoetin alfa SC | Phase 2 | Anemia | - | - |
HZN-1116 | Phase 2 | Sjogren's Syndrome | - | - |
AMG 337 | Phase 2 | Stomach Neoplasms | - | - |
pegfilgrastim 12 mg | Phase 2 | Lymphoma | - | - |
Investigator's Choice Chemotherapy | Phase 2 | High-risk Diffuse Large B-Cell Lymphoma | - | - |
Rozibafusp Alfa | Phase 2 | Systemic Lupus Erythematosus (SLE) | - | - |
5-Fluorouracil | Phase 2 | Colorectal Cancer | - | - |
Panitumumab (ABX-EGF) | Phase 2 | Advanced Renal Cell Carcinoma | - | - |
Talimogene laherparepvec | Phase 2 | Melanoma | - | - |
AMG 853 | Phase 2 | Asthma | - | - |
epratuzumab | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
cinacalcet (AMG 073) | Phase 2 | Secondary Hyperparathyroidism | - | - |
AMG 193 | Phase 2 | MTAP-deleted NSCLC | - | - |
Apremilast 10mg | Phase 2 | Psoriasis | - | - |
Antizol | Phase 2 | Aldehyde Dehydrogenase-2 (ALDH2) Deficiency | - | - |
VIB7734 | Phase 2 | Lupus Erythematosus, Systemic | - | - |
Systemic AMG 108 | Phase 2 | Osteoarthritis | - | - |
Modified FOLFOX6 | Phase 2 | Advanced Solid Tumors | - | - |
Blinatumomab (MT103) | Phase 2 | Acute Lymphoblastic Leukemia | - | - |
AMG 334 | Phase 2 | Post-Traumatic Headache | - | - |
AMG 827 | Phase 2 | Asthma | - | - |
IV Bisphosphonate q 4 weeks | Phase 2 | Bone Metastases in Men With Hormone-Refractory Prostate Cancer | - | - |
Pegsunercept (PEG sTNF-RI) | Phase 2 | Rheumatoid Arthritis | - | - |
MP-376 | Phase 2 | Cystic Fibrosis (CF) | - | - |
AMG 386 10mg/kg | Phase 2 | Gastrointestinal Cancer | - | - |
Lodotra | Phase 2 | Asthma | - | - |
CPT-11 | Phase 2 | Non Small Cell Lung Cancer | - | - |
Naproxen | Phase 2 | Bone Pain in Stage I - III Breast Cancer | - | - |
CCX282-B | Phase 2 | Crohn's Disease | - | - |
Teriparatide | Phase 2 | Low Bone Mineral Density | - | - |
5FU | Phase 2 | Squamous Cell Carcinoma of Head and Neck | - | - |
Carfilzomib | Phase 2 | Multiple Myeloma | - | - |
anakinra | Phase 2 | Rheumatoid Arthritis | - | - |
CC-10004 | Phase 2 | Psoriasis | - | - |
CCX140-B | Phase 2 | Diabetic Nephropathy | - | - |
AMG 317 75 mg | Phase 2 | Asthma | - | - |
AMG 223 | Phase 2 | End Stage Renal Disease | - | - |
Oprozomib | Phase 2 | Multiple Myeloma | - | - |
AMG 102 at 10 mg/kg | Phase 2 | Advanced Renal Cell Carcinoma | - | - |
AMG 655 | Phase 2 | Metastatic Colorectal Cancer | - | - |
BUPHENYL® | Phase 2 | Urea Cycle Disorders | - | - |
CCX-354-C | Phase 2 | Rheumatoid Arthritis | - | - |
100 mg AMG 162 | Phase 2 | Osteoporosis | - | - |
Liatermin | Phase 2 | Parkinson's Disease | - | - |
NaPBA | Phase 2 | Urea Cycle Disorders | - | - |
Previous denosumab | Phase 2 | Low Bone Mass | - | - |
filgrastim | Phase 2 | Sarcoma | - | - |
Daxdilimab | Phase 2 | Alopecia Areata | - | - |
Sensipar (Cinacalcet HCl) | Phase 2 | Secondary Hyperparathyroidism | - | - |
ABX-EGF | Phase 2 | Non-small Cell Lung Cancer | - | - |
Motesanib diphosphate | Phase 2 | Lung Cancer | - | - |
VIB4920 | Phase 2 | Sjögren's Syndrome | - | - |
AMG 151 | Phase 2 | Diabetes Mellitus | - | - |
Intra-articular metHuIL-1ra (anakinra) | Phase 2 | Osteoarthritis | - | - |
Belatacept | Phase 2 | Allografts | - | - |
Conatumumab | Phase 2 | Colon Cancer | - | - |
liposomal cytarabine | Phase 2 | Primary Disease | - | - |
Cytarabine | Phase 2 | Lymphoma | - | - |
IV iron dextran | Phase 2 | Anemia | - | - |
Neulasta | Phase 2 | Breast Cancer | - | - |
CEEP regimen | Phase 2 | Lymphoma | - | - |
AMG 714 | Phase 2 | Psoriasis | - | - |
CC-11050 | Phase 2 | Cutaneous Lupus Erythematosus | - | - |
AMG 102 | Phase 2 | Cancer | - | - |
Ezetimibe | Phase 2 | Hyperlipidemia | - | - |
RCHOP | Phase 2 | Richter Syndrome | - | - |
Romidepsin | Phase 2 | Peripheral T Cell Lymphoma | - | - |
AMG 719 | Phase 2 | Rheumatoid Arthritis | - | - |
AMG 301 | Phase 2 | Chronic Migraine or Episodic Migraine | - | - |
AMG 732 | Phase 2 | Thyroid Eye Disease | - | - |
Abrilumab | Phase 2 | Ulcerative Colitis | - | - |
Erenumab PFS | Phase 2 | Migraine | - | - |
Brodalumab | Phase 2 | Rheumatoid Arthritis | - | - |
AMG 509 | Phase 1 | Prostate Cancer | Fast Track | - |
KRAS G12C NSCLC
1 drug in this indication
Small Cell Lung Cancer
1 drug in this indication
Prostate Cancer
1 drug in this indication
reduction of cardiovascular risk, prevention of first myocardial infarction or stroke
1 drug in this indication
Cardiovascular risk reduction, primary prevention of myocardial infarction and stroke
1 drug in this indication
Reduction of risk of first myocardial infarction or stroke in patients with cardiovascular disease
1 drug in this indication
primary prevention of myocardial infarction and stroke
1 drug in this indication
rare disease
1 drug in this indication
Reduction of risk of first myocardial infarction or stroke
1 drug in this indication
reduction of risk of first heart attack or stroke
1 drug in this indication
lung cancer
1 drug in this indication
Systemic Lupus Erythematosus (SLE)
1 drug in this indication
Rheumatoid Arthritis
1 drug in this indication
rare kidney disease
1 drug in this indication
ANCA-associated vasculitis (AAV)
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Amgen Inc.'s drug pipeline?→
CatalystAlert tracks 212 drug candidates in Amgen Inc.'s (AMGN) pipeline across Phase 3, Phase 2, Phase 1, Approved. Its lead program is Pegloticase (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Amgen Inc.'s next FDA catalyst?→
Amgen Inc.'s (AMGN) next tracked catalyst is a Phase 3 expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AMGN biotech catalysts?→
Add AMGN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Amgen Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.